Online inquiry

IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13749MR)

This product GTTS-WQ13749MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ANGPTL3 gene. The antibody can be applied in Hypertriglyceridemia&Homozygous familial hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014495.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27329
UniProt ID Q9Y5C1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13749MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5950MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ9877MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ986MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ8770MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ9322MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMP-321
GTTS-WQ12290MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ9093MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ6947MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW